Abstract
Main goal in drug discovery is the identification of drug-like compounds capable to modulate specific biological targets. Thus, the prediction of reliable binding poses of candidate ligands, through molecular docking simulations, represents a key step to be pursued in structure-based drug design (SBDD). Since the increasing number of resolved three-dimensional ligand-protein structures, together with the expansion of computational power and software development, the comprehensive and systematic use of experimental data can be proficiently employed to validate the docking performance. This allows to select and refine the protocol to adopt when predicting the binding pose of trial compounds in a target. Given the availability of multiple docking software, a comparative docking assessment in an early research stage represents a must-use step to minimize fails in molecular modeling. This chapter describes how to perform a docking assessment, using freely available tools, in a semiautomated fashion.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Persch E, Dumele O, Diederich F (2015) Molecular recognition in chemical and biological systems. Angew Chem Int Ed Eng 54(11):3290–3327. https://doi.org/10.1002/anie.201408487
Yu W, MacKerell AD Jr (2017) Computer-aided drug design methods. Methods Mol Biol 1520:85–106. https://doi.org/10.1007/978-1-4939-6634-9_5
Tang YT, Marshall GR (2011) Virtual screening for lead discovery. Methods Mol Biol 716:1–22. https://doi.org/10.1007/978-1-61779-012-6_1
Ballante F, Ragno R (2012) 3-D QSAutogrid/R: an alternative procedure to build 3-D QSAR models. Methodologies and applications. J Chem Inf Model 52(6):1674–1685. https://doi.org/10.1021/ci300123x
Ballante F, Reddy DR, Zhou NJ et al (2017) Structural insights of SmKDAC8 inhibitors: targeting schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy. Bioorg Med Chem 25(7):2105–2132. https://doi.org/10.1016/j.bmc.2017.02.020
Kubinyi H (1993) 3D QSAR in drug design. Volume 1: theory methods and applications. Three-dimensional quantitative structure activity relationships, Vol. 1. Springer, Berlin
Oprea TI, Waller CL (1997) Theoretical and practical aspects of three-dimensional quantitative structure-activity relationships. In: Reviews in computational chemistry. Wiley, Hoboken, NJ, pp 127–182. https://doi.org/10.1002/9780470125885.ch3
Bursulaya BD, Totrov M, Abagyan R et al (2003) Comparative study of several algorithms for flexible ligand docking. J Comp Aided Molec Design 17(11):755–763. https://doi.org/10.1023/B:Jcam.0000017496.76572.6f
Stahl M (2000) Modifications of the scoring function in FlexX for virtual screening applications. Perspect Drug Discov Design 20(1):83–98. https://doi.org/10.1023/A:1008724921888
Wang R, Lu Y, Fang X et al (2004) An extensive test of 14 scoring functions using the PDBbind refined set of 800 protein-ligand complexes. J Chem Inf Comput Sci 44(6):2114–2125. https://doi.org/10.1021/ci049733j
Reddy DR, Ballante F, Zhou NJ et al (2017) Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors. Eur J Med Chem 127:531–553. https://doi.org/10.1016/j.ejmech.2016.12.032
Pettersen EF, Goddard TD, Huang CC et al (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612. https://doi.org/10.1002/jcc.20084
Morris GM, Huey R, Lindstrom W et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791. https://doi.org/10.1002/jcc.21256
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461. https://doi.org/10.1002/jcc.21334
Maignan S, Guilloteau JP, Pouzieux S et al (2000) Crystal structures of human factor Xa complexed with potent inhibitors. J Med Chem 43(17):3226–3232
Kamata K, Kawamoto H, Honma T et al (1998) Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc Natl Acad Sci U S A 95(12):6630–6635
Scharer K, Morgenthaler M, Paulini R et al (2005) Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand. Angew Chem Int Ed Eng 44(28):4400–4404. https://doi.org/10.1002/anie.200500883
Watson NS, Brown D, Campbell M et al (2006) Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors. Bioorg Med Chem Lett 16(14):3784–3788. https://doi.org/10.1016/j.bmcl.2006.04.053
Pinto DJ, Orwat MJ, Quan ML et al (2006) 1-[3-Aminobenzisoxazol-5’-yl]-3-trifluoromethyl-6-[2’-(3-(R)-hydroxy-N-pyrrolidin yl)methyl-[1,1’]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett 16(15):4141–4147. https://doi.org/10.1016/j.bmcl.2006.02.069
Ballante F, Marshall GR (2016) An automated strategy for binding-pose selection and docking assessment in structure-based drug design. J Chem Inf Model 56(1):54–72. https://doi.org/10.1021/acs.jcim.5b00603
Allen WJ, Balius TE, Mukherjee S et al (2015) DOCK 6: Impact of new features and current docking performance. J Comput Chem 36(15):1132–1156. https://doi.org/10.1002/jcc.23905
O’Boyle NM, Banck M, James CA et al (2011) Open Babel: an open chemical toolbox. Aust J Chem 3:33. https://doi.org/10.1186/1758-2946-3-33
The Open Babel Package. 2.4.1 http://openbabel.org. Accessed June 2017. edn.
Berman HM, Westbrook J, Feng Z et al (2000) The protein data bank. Nucleic Acids Res 28(1):235–242
Acknowledgments
F.B. thanks Prof. Garland R. Marshall (Washington University School of Medicine in St. Louis, MO) for supporting and funding the design and development of the Clusterizer-DockAccessor protocol; Dr. Chris M. W. Ho (Drug Design Methodologies, LLC, St. Louis, MO) and Ms. Mariama Jaiteh (Uppsala University, Uppsala, Sweden) for providing insightful comments.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Ballante, F. (2018). Protein-Ligand Docking in Drug Design: Performance Assessment and Binding-Pose Selection. In: Mavromoustakos, T., Kellici, T. (eds) Rational Drug Design. Methods in Molecular Biology, vol 1824. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8630-9_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8630-9_5
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8629-3
Online ISBN: 978-1-4939-8630-9
eBook Packages: Springer Protocols